10-Q: Crinetics Q3 2025: PALSONIFY Approved, Pipeline Advances

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, significant R&D pipeline progress, and increased operating losses in its Q3 2025 filing.

Summary

• FDA approved PALSONIFY (paltusotine) on September 25, 2025, for first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
• Net loss for the nine months ended September 30, 2025, increased to $342.5 million from $217.8 million in the prior year period.
• Research and development expenses rose by 42% to $247.0 million for the nine months ended September 30, 2025, driven by clinical program advancement and preclinical portfolio.
• Selling, general and administrative expenses surged by 92% to $137.6 million for the nine months ended September 30, 2025, primarily due to increased headcount and commercial launch activities for PALSONIFY.
• Cash, cash equivalents, and investment securities totaled $1.1 billion as of September 30, 2025, down from $1.35 billion at December 31, 2024.
• Positive Phase 2 results for atumelnant in CAH were reported in January 2025, showing rapid, substantial, and sustained reduction in A4 levels.
• IND clearance was received for CRN09682, a nonpeptide drug conjugate, with a Phase 1/2 study for neuroendocrine tumors expected to begin in Q4 2025.
• The company maintains a 25% ownership in Radionetics Oncology, which formed a strategic partnership with Eli Lilly and Company, including a $140.0 million upfront payment and a potential $1.0 billion acquisition right for Lilly.

Sentiment

Score: 4

Explanation: While the FDA approval of PALSONIFY is a significant positive, the substantial increase in net losses and cash burn, coupled with delays in some pipeline programs and the explicit need for future capital raises, indicates a challenging financial period. The commercialization costs are high, and product revenue has not yet materialized, leading to a negative financial outlook despite clinical progress.

Positives

• FDA approval of PALSONIFY (paltusotine) on September 25, 2025, for first-line treatment of acromegaly.
• EMA granted Orphan Drug Designation for paltusotine for acromegaly, with a potential EMA decision in the first half of 2026.
• Positive Phase 2 TouCAHn open-label study results for atumelnant in CAH, demonstrating statistically significant reduction in A4 levels and significant clinical improvements.
• Initiation of an open-label extension study for atumelnant in CAH and planned initiation of the BALANCE-CAH pediatric study in Q4 2025.
• IND clearance for CRN09682, the first candidate from the nonpeptide drug conjugate platform, with a Phase 1/2 study expected to enroll the first patient in Q4 2025.
• Strategic partnership between Radionetics (25% owned by Crinetics) and Eli Lilly and Company, including a $140.0 million upfront payment to Radionetics and a potential $1.0 billion acquisition right for Lilly.
• Crinetics is eligible to receive total potential sales milestones in excess of $300.0 million and single-digit royalties on net sales from the Radionetics license.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 57% to $342.5 million compared to $217.8 million in the prior year period.
• Operating expenses increased significantly, with research and development up 42% to $247.0 million and selling, general and administrative up 92% to $137.6 million for the nine months ended September 30, 2025.
• Net cash used in operating activities increased by 75% to $285.0 million for the nine months ended September 30, 2025, indicating a higher cash burn rate.
• Cash, cash equivalents, and investment securities decreased by $261.8 million from December 31, 2024, to September 30, 2025.
• The company has an accumulated deficit of $1.3 billion as of September 30, 2025, and expects to continue incurring net losses for the foreseeable future.
• The TSHR antagonist program has shifted focus to an alternative candidate due to the need for a superior profile.
• The IND submission for the SST3 program will be postponed due to the need for follow-up preclinical work.

Risks

• The company has a limited operating history, has incurred significant operating losses since its inception, and expects to continue to incur losses.
• Prospects are highly dependent on the successful launch and commercialization of PALSONIFY and other late-stage clinical drug candidates.
• Commercial success of PALSONIFY will depend on the degree of market acceptance by physicians, patients, third-party payors, and others in the health care community.
• Failure to generate enough revenue from commercial sales of PALSONIFY could materially adversely affect the business, financial condition, results of operations, and stock price.
• The company may never generate revenue from commercial sales or successfully commercialize other drug candidates if they are not successfully developed and approved.
• Failure to become and remain profitable would depress the value of the company and could impair its ability to raise capital, expand its business, maintain R&D efforts, diversify product candidates, or continue operations.
• The company may need to raise substantial additional capital in the future, and there is no assurance as to the availability or terms of such financing.
• The process of testing product candidates in clinical trials is costly, and the timing of progress and expenses is uncertain.
• The U.S. federal government has been shut down since October 1, 2025, and the impact of a prolonged government shutdown on business and economic conditions, and on the company's financial position, is uncertain.

Future Outlook

The company expects operating expenses to increase in future periods as product revenues from PALSONIFY increase and as it conducts ongoing and planned clinical trials, research and development activities, and preclinical studies. Operating losses are anticipated to increase until substantial product revenues can support the cost structure. The company believes existing capital is sufficient for at least the next 12 months but expects to need substantial additional capital over the next several years, planning to fund needs through product sales, equity offerings, debt financings, or collaborations.

Management Comments

• "Our vision is to build the premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients."
• "We expect product revenues to increase as we continue to expand our commercial activities."
• "We expect our operating losses will increase in future periods until such time, if ever, we can generate substantial product revenues to support our cost structure."
• "We plan to increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and the discovery of new product candidates."

Industry Context

Crinetics operates in the specialized field of endocrine diseases and endocrine-related tumors, a niche within the biopharmaceutical industry often characterized by high unmet medical needs and potential for orphan drug designations. The FDA approval of PALSONIFY for acromegaly positions the company to compete in a market with existing injectable somatostatin receptor ligands, offering a potential oral alternative. The pipeline expansion into CAH, ADCS, neuroendocrine tumors, Graves disease, and ADPKD demonstrates a strategy to leverage expertise in GPCRs across multiple rare and complex endocrine conditions. The strategic partnership of Radionetics with Eli Lilly highlights the significant interest and investment in radiotherapeutics within the broader oncology space.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies or projects.
• The market research on acromegaly patients (36,000 in the US, 11,500 actively managed, 40% treatment naive) provides context for PALSONIFY's market opportunity but no direct comparison to competitor performance.
• The partnership between Radionetics and Eli Lilly, with a $140 million upfront payment and a potential $1 billion acquisition, indicates a strong valuation for radiotherapeutics technology, which is a positive signal for Crinetics' 25% stake in Radionetics.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• From time to time, the company may be subject to various claims and suits arising in the ordinary course of business, which are not expected to have a material adverse effect.

Related Party Transactions

• R. Scott Struthers, Ph.D., the company's President and Chief Executive Officer, serves as chairman of the Radionetics board of directors and receives consideration in the form of both equity and a $50,000 annual retainer for his service. As of September 30, 2025, Dr. Struthers has an approximately 1.3% ownership stake in Radionetics.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings; increased operating losses and cash burn may negatively impact share price; FDA approval of PALSONIFY and pipeline progress offer long-term growth potential.
• Employees: Increased headcount and stock-based compensation indicate growth in workforce; deferred compensation plan and stock purchase plan offer benefits.
• Customers (Patients): FDA approval of PALSONIFY provides a new treatment option for acromegaly; pipeline development aims to address unmet needs in other endocrine diseases.
• Creditors/Suppliers: Increased accounts payable and accrued expenses suggest higher operational activity; potential for extended payment terms if additional funding is not secured.
• Regulatory Authorities: Ongoing review by EMA for PALSONIFY and IND clearances for new candidates demonstrate continued engagement with regulatory bodies.

Next Steps

• Continue commercialization efforts for PALSONIFY in the U.S.
• Await EMA decision for paltusotine for acromegaly in the first half of 2026.
• Continue clinical development of paltusotine for carcinoid syndrome.
• Continue development program for atumelnant, with data from Cohort 4 of adult Phase 2 study expected early 2026.
• Initiate the BALANCE-CAH pediatric study for atumelnant in Q4 2025.
• Initiate the Phase 2/3 trial of atumelnant in ADCS in the first half of 2026.
• Initiate Phase 1/2 dose escalation study of CRN09682, with the first patient expected in Q4 2025.
• Advance an alternative candidate for the TSHR antagonist program.
• Conduct follow-up preclinical work for the SST3 program to enable future IND submission.
• Continue international expansion activities.

Key Dates

Recommendation

The FDA approval of PALSONIFY is a significant positive catalyst, validating the company's drug development capabilities and opening a new commercialization phase. However, this positive is tempered by a substantial increase in net losses and cash burn, driven by aggressive R&D and commercial launch expenses. While the pipeline shows promising progress with atumelnant and new INDs, there are also setbacks with the TSHR and SST3 programs. The company explicitly states the need for substantial additional capital, which could lead to future dilution. Given the high burn rate and the early stage of commercialization for PALSONIFY (no product revenue yet), the stock presents a mixed risk-reward profile. A "hold" recommendation is appropriate for investors to observe the initial commercial traction of PALSONIFY and the progress of the late-stage pipeline, while acknowledging the significant financial outlays and future funding requirements.

Keywords

Crinetics Pharmaceuticals, CRNX, SEC Filing, 10-Q, Pharmaceuticals, Biotechnology, Endocrine Diseases, Acromegaly, PALSONIFY, Paltusotine, Congenital Adrenal Hyperplasia, CAH, Atumelnant, ACTH-Dependent Cushing's Syndrome, ADCS, Neuroendocrine Tumors, CRN09682, Nonpeptide Drug Conjugate, SST2 Agonist, Graves Disease, Thyroid Eye Disease, TSHR Antagonist, CRN12755, Polycystic Kidney Disease, ADPKD, SST3 Agonist, CRN10329, Clinical Trials, FDA Approval, EMA Review, Orphan Drug Designation, Financial Results, Net Loss, R&D Expenses, SG&A Expenses, Cash Flow, Liquidity, Capital Raise, Radionetics Oncology, Eli Lilly, Strategic Partnership